By Matthew Heller ( April 29, 2013, 10:24 PM EDT) -- Eli Lilly & Co. urged a California federal judge on Monday to toss a class action alleging inadequate labeling of its antidepressant Cymbalta, saying it sufficiently disclosed to doctors the risk that discontinuing use of the drug would cause "brain zaps" and other side effects....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.